• Ollin Biosciences

  Participated · Series B · Jun 2026

  Ollin Biosciences, founded in 2023 and based in Austin, Texas, is advancing a pipeline of bispecific antibodies for retinal and orbital diseases. Its lead candidate, OLN324, is a next-generation VEGF/Ang2 bispecific antibody discovered in collaboration with Innovent Biologics; in a 164-patient randomized head-to-head Phase 1b (JADE) study versus faricimab (Vabysmo®) OLN324 demonstrated faster and greater anatomic retinal drying and numerically greater vision gains. Ollin plans to initiate global Phase 3 trials of OLN324 in DME and wAMD in the second half of 2026 after completing regulatory discussions with the FDA and receiving EMA scientific advice. The company’s second program, OLN102, is a TSHR/IGF-1R bispecific antibody discovered with VelaVigo and is expected to enter clinical development in 2026 for thyroid eye disease and Graves’ disease. Ollin positions its candidates as potentially best-in-disease therapies and is using recent financing to fund registrational studies and further clinical development.

• Thyme Care

  Participated · Series B · Aug 2023

  Founded in 2020, Thyme Care builds an integrated oncology infrastructure that aligns payers, providers, employers, and patients around value-based care. Its technology stack combines AI-driven orchestration, advanced data analytics, and a virtual/hybrid care team of doctors, nurses, social workers, and care partners to guide patients through every stage of the cancer journey. The company now partners with more than 1,000 oncologists and reaches 8 million covered lives, managing over $5 billion in oncology spend. Outcomes include 90% of members feeling more supported, 72% proactively submitting ePRO updates, 40% fewer ER visits, and 19% fewer hospital admissions among engaged members. One partner practice saved nearly 2,000 staff hours in a year, underscoring efficiency gains. Thyme Care achieved profitability ahead of its Series D raise, demonstrating a sustainable business model. Looking forward, the company plans to deepen AI integration to automate documentation, surface real-time insights, and eliminate additional bottlenecks in cancer care. By scaling these capabilities, Thyme Care aims to serve as the backbone for more connected, accountable, and compassionate oncology care nationwide.

• Orbital Therapeutics

  Participated · Series A · Apr 2023

  Orbital Therapeutics is building a first-in-kind RNA platform that integrates established and emerging RNA technologies, delivery mechanisms, data science and automation to broaden the reach of RNA medicines. The company is focused on next-generation vaccines, immunomodulation, and protein replacement, and seeks to extend the durability of RNA therapeutics while expanding delivery to a wide range of cell types and tissues. Orbital excludes small interfering RNA from its stated remit and emphasizes platform-driven discovery and development. The company describes itself as founded by experts in genetic medicine and RNA development and delivery. Recent corporate growth included executive hires to support development and operations. The financing announced will support expansion of the platform and portfolio toward patient-facing programs.

• Maze Therapeutics

  Participated · Equity · Jan 2022

  Maze Therapeutics is a clinical-stage biopharmaceutical company that uses human genetics and its Compass platform to develop novel small-molecule precision medicines for renal, cardiovascular and related metabolic diseases. Its pipeline is led by two wholly owned lead programs, MZE829 (an oral APOL1 inhibitor) and MZE782 (an oral SCL6A19 inhibitor). MZE829 is being evaluated for APOL1 kidney disease, including focal segmental glomerulosclerosis (FSGS), with a Phase 2 trial expected to begin by Q1 2025. MZE782 is in a Phase 1 healthy volunteer trial with plans to evaluate it for chronic kidney disease (CKD) and phenylketonuria (PKU); Phase 1 data are expected in the second half of 2025. The company announced an oversubscribed $115 million Series D financing (which included conversion of issued convertible notes previously purchased by existing investors) to support advancement of these clinical programs and future pipeline work. Maze is based in South San Francisco, Calif., and intends to use the financing to optimize its upcoming Phase 2 trial and further explore the potential of both lead programs. Maze Therapeutics applies advanced data science, human genetics and functional genomics via its Maze Compass platform to discover small-molecule and biologic therapies for genetically defined disorders. The company has generated nine programs and two joint ventures since its 2019 launch and is advancing programs across rare and common genetically defined diseases. Its most advanced programs include MZE001 for Pompe disease, an APOL1 program for chronic kidney disease, and an ATXN2 program for amyotrophic lateral sclerosis (ALS). MZE001 is expected to enter the clinic in the first half of 2022 as the company transitions to clinical-stage development. Maze intends to use its platform and the recent financing to expand variant functionalization and accelerate end-to-end computational chemistry–informed drug discovery. The company is based in South San Francisco. Maze Therapeutics was launched to translate human genetic insights—specifically genetic modifiers—into novel therapeutics. The company aims to expand understanding of natural disease protection provided by genetic modifiers by combining global studies of human genetic variation with large-scale gene perturbation experiments. Maze plans to use those integrated insights to create medicines built around protective modifier genes to treat multiple diseases. The company announced an initial investment commitment of $191 million to support its launch and R&D activities. Maze has assembled a team of prominent scientific founders and senior leaders to drive discovery and drug development.

No current team members are available.